Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome
- 170 Downloads
Early risk stratification in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) is important since the benefit from more aggressive and costly treatment strategies is proportional to the risk of adverse clinical events. In the present study we assessed whether hybrid single photon emission computed tomography (SPECT)/coronary computed tomography angiography (CCTA) technology could be an appropriate tool in stratifying patients with NSTE-ACS.
SPECT/CCTA was performed in 90 consecutive patients with NSTE-ACS. The Thrombolysis in Myocardial Infarction risk score (TIMI-RS) was used to classify patients as low- or high-risk. Imaging was performed using SPECT/CCTA to identify haemodynamically significant lesions defined as >50% stenosis on CCTA with a reversible perfusion defect on SPECT in the corresponding territory.
CCTA demonstrated at least one lesion with >50% stenosis in 35 of 40 high-risk patients (87%) as compared to 14 of 50 low-risk patients (35%; TIMI-RS <3; p <0.0001). Of the 40 high-risk and 50 (16%) low-risk TIMI-RS patients, 16 (40%) and 8 (16%), respectively, had haemodynamically significant lesions (p = 0.01). Patients defined as high-risk by a high TIMI-RS, a positive CCTA scan or both (n = 45) resulted in a sensitivity of 95%, specificity of 49%, PPV of 35% and NPV of 97% for having haemodynamically significant coronary lesions. Those with normal perfusion were spared revascularization procedures, regardless of their TIMI-RS.
Noninvasive assessment of coronary artery disease by SPECT/CCTA may play an important role in risk stratification of patients with NSTE-ACS by better identifying the subgroup requiring intervention.
KeywordsMyocardial perfusion imaging SPECT/CT Coronary artery disease CT coronary angiography
Conflicts of interest
Ora Israel: advisor to GE Healthcare.
All other authors declare that they have no conflicts of interest.
- 4.Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879–87.PubMedCrossRefGoogle Scholar
- 5.Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23(3):223–9. doi: 10.1053/euhj.2001.2738.PubMedCrossRefGoogle Scholar
- 6.Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292(17):2096–104. doi: 10.1001/jama.292.17.2096.PubMedCrossRefGoogle Scholar
- 7.Fox KA, Goodman SG, Anderson Jr FA, Granger CB, Moscucci M, Flather MD et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24(15):1414–24. doi: 10.1016/S0195-668X(03)00315-4.PubMedCrossRefGoogle Scholar
- 9.Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. 1999;354(9192):1757–62. doi: 10.1016/S0140-6736(99)10285-X.PubMedCrossRefGoogle Scholar
- 10.Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol. 1997;29(1):43–8. doi: 10.1016/S0735-1097(96)00447-0.PubMedCrossRefGoogle Scholar
- 11.Hoffmann U, Bamberg F, Chae CU, Nichols JH, Rogers IS, Seneviratne SK, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009;53(18):1642–50. doi: 10.1016/j.jacc.2009.01.052.PubMedCrossRefGoogle Scholar
- 12.Rispler S, Keidar Z, Ghersin E, Roguin A, Soil A, Dragu R, et al. Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. J Am Coll Cardiol. 2007;49(10):1059–67. doi: 10.1016/j.jacc.2006.10.069.PubMedCrossRefGoogle Scholar
- 14.Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med. 2006;166(13):1391–5. doi: 10.1001/archinte.166.13.1391.PubMedCrossRefGoogle Scholar
- 16.Samaha FF, Kimmel SE, Kizer JR, Goyal A, Wade M, Boden WE. Usefulness of the TIMI risk score in predicting both short- and long-term outcomes in the Veterans Affairs Non-Q-Wave Myocardial Infarction Strategies In-Hospital (VANQWISH) Trial. Am J Cardiol. 2002;90(9):922–6. doi: 10.1016/S0002-9149(02)02654-1.PubMedCrossRefGoogle Scholar
- 17.F Ragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708–15. doi: 10.1016/S0140-6736(99)07349-3.CrossRefGoogle Scholar
- 18.Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004;109(7):874–80. doi: 10.1161/01.CIR.0000112604.74713.35.PubMedCrossRefGoogle Scholar
- 21.Gaemperli O, Schepis T, Kalff V, Namdar M, Valenta I, Stefani L, et al. Validation of a new cardiac image fusion software for three-dimensional integration of myocardial perfusion SPECT and stand-alone 64-slice CT angiography. Eur J Nucl Med Mol Imaging. 2007;34(7):1097–106. doi: 10.1007/s00259-006-0342-9.PubMedCrossRefGoogle Scholar
- 25.Heller GV, Stowers SA, Hendel RC, Herman SD, Daher E, Ahlberg AW, et al. Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms. J Am Coll Cardiol. 1998;31(5):1011–7. doi: 10.1016/S0735-1097(98)00057-6.PubMedCrossRefGoogle Scholar
- 26.Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000;356(9223):9–16.PubMedCrossRefGoogle Scholar
- 27.Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40(7):1366–74. doi: 10.1016/S0735-1097(02)02336-7.PubMedCrossRefGoogle Scholar
- 29.Sharis PJ, Cannon CP, Rogers WJ, McCabe C, Murphy S, Gibson CM, et al. Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). Am J Cardiol. 2002;90(10):1154–6. doi: 10.1016/S0002-9149(02)02788-1.PubMedCrossRefGoogle Scholar
- 30.Zia MI, Goodman SG, Peterson ED, Mulgund J, Chen AY, Langer A, et al. Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. Can J Cardiol. 2007;23(13):1073–9.PubMedCrossRefGoogle Scholar
- 35.Shaw LJ, Heller GV, Travin MI, Lauer M, Marwick T, Hachamovitch R, et al. Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain. Economics of Noninvasive Diagnosis (END) Study Group. J Nucl Cardiol. 1999;6(6):559–69. doi: 10.1016/S1071-3581(99)90091-0.PubMedCrossRefGoogle Scholar